

Research Article

**IN VIVO ANTIARTHRITIC ACTIVITY OF THE METHANOLIC AND N-HEXANE EXTRACTS OF LEAVES OF *PENTAS LANCEOLATA* (FORSSK.) DEFLERS IN FREUND'S COMPLETE ADJUVANT INDUCED ARTHRITIS**

**PRAGATI KUMAR<sup>1\*</sup>, PRANAY WAL<sup>1\*</sup>, AWANI KUMAR RAI<sup>2</sup>, YATENDRA SINGH<sup>2</sup>, ASHISH KUMAR SHARMA<sup>3</sup>**

<sup>1\*</sup>Pranveer Singh Institute of Technology (Pharmacy), Bhauti Kanpur, Uttar Pradesh, India.

<sup>2</sup>Pranveer Singh Institute of Technology (Pharmacy), Bhauti Kanpur, Uttar Pradesh, India.

<sup>3</sup>Nims Institute of Pharmacy, NIMS University Shobha Nagar Jaipur Rajasthan, India.

**\*Corresponding Author:**

Pragati Kumar

Department of Pharmacognosy

Pranveer Singh Institute of technology (Pharmacy)

NH-2 Bhauti, Kanpur Uttar Pradesh - 209305

Phone: - +919694504247

E-mail- [kumarkpragati@gmail.com](mailto:kumarkpragati@gmail.com)

**ABSTRACT**

Arthritis is a chronic immobilizing, skeletal and muscular disorder having quite similar symptoms as that of rheumatoid arthritis (RA) for which currently there is no medicine available for permanent cure. All modern drugs provide symptomatic temporary relief, but produce severe side effects. *Pentas lanceolata* having some ethnomedicinal record to treat the symptoms of arthritis. So, this study has been aimed at the validation of its traditional claim about anti-arthritic efficacy. In present study the methanolic and n-hexane extracts of *Pentas lanceolata* leaves were evaluated in CFA (Complete Freund's Adjuvant) induced arthritis in male wistar rats for assessment in oedema on **day 28**. CFA-induced inflammatory paw oedema, total arthritic scores, arthritic index, complete haematological & radiological parameters were all evaluated for the assessment of disease progression. The analysis of various arthritic assessment parameters used in this study revealed that *P. lanceolata* extracts have a considerable effect in preventing development or

ameliorate arthritis disease severity in both normal and CFA-induced arthritis rats in a dose-dependent manner.

**Keywords:** Arthritis, *Pentas lanceolata*, MEPL & HEPL (Methanolic & n-Hexane extracts of *P. lanceolata*), Indomethacin, Freund's complete adjuvant, Paw volume

## INTRODUCTION

Arthritis is a broad term that covers more than hundred diseases. It may be related with joints, the site of bones connection, such as wrists, knees, hips, or fingers etc. Some types of arthritis can also affect some connective tissues and organs, including skin<sup>[1]</sup>. There are some evidences suggest that abnormalities in components of the immune system that direct to the body developing and inflammatory reactions, particularly in joints are the major causes of arthritis<sup>[2]</sup>. These features result in quick loss of muscle around an affected joint with the pain and swelling lead to loss of joint function. There are some more causes that can raise chances of getting arthritis like Age, gender, genes as well as injuries<sup>[3]</sup>. Symptoms of arthritis includes pain around the joints, swelling of joints, redness or feel warm to the touch of joints and difficulty in moving etc. The most common types of arthritis are Osteoarthritis, Rheumatoid arthritis and Gout<sup>[4]</sup>.

The prevalence of rheumatoid arthritis is about 1.5 % of the world population and the epidemiology of arthritis in male to female ratio is 3:1<sup>[5]</sup>. Since RA is a chronic disease, the treatment mainly focuses on improving pain, avert or limit joint damage, improve or preserve function of the joints and optimize the quality of life<sup>[6]</sup>. Cytokines play a major role in inflammation and damage the joint leading to tissue destruction during the development of RA which includes the tumour necrosis factor- $\alpha$ , interleukin-1 $\beta$  and IL-6<sup>[7]</sup>. NSAID and disease altering anti-rheumatoid drugs have many applications in treating diseases but are accompanying with side effects like GI complications, ulcers and cardiovascular problems<sup>[8-10]</sup>. Major problems of the currently available drugs for RA include poor efficacy, potential side effects and high cost of biological agents. Thus, a competent and safe alternate from plants has drawn special attention from scientists worldwide.

*Pentas lanceolata* (Family-Rubiaceae), commonly known as Egyptian Star, is native to tropical Africa and is commonly used as herbal medicine in Ethiopia, Uganda, Rwanda and Kenya. This is erect evergreen perennial shrub, 3 to 4 feet tall and is tinted all over most of the year with 3-inch-wide, dense clusters of long-tubed, star-shaped flowers available in white, pink, red, and lavender colour. The plants grow commonly during summer season. Leaves and stems are enclosed with fine hairs, and leaves have prominent veins on the

undersides. Traditionally the plant is most popular and various parts of the plant are used as in the treatment of diseases like Lymphadenitis, Diarrhoea, Malaria, Ascariasis, Snake bite etc<sup>[11-14]</sup>.

The preceding phytochemical investigation of *Pentas lanceolata* leaves with Methanol and n-Hexane extract reveals the presence of glycosides (3.5-6.0 %), terpenoids (0.5-1.0 %), sterols (0.2-0.5 %) and traces of flavonoids and carbohydrates. Anthraquinone glycosides were also isolated from the leaves of the plants named as Rubiadin-1-methyl ether, Damnacanthol, Rubiadin, Lucidin- $\omega$ -methyl ether etc<sup>[15]</sup>. Some studies reported about the medicinal importance of these anthraquinones as in the treatment of malaria and lymphadenitis<sup>[12-13]</sup>. Thus, this research was conducted to find more evidence about the use of natural resources of *P. lanceolata* leaves as anti-arthritis.

## MATERIALS AND METHODS

### Plant Material

The fresh leaves of *Pentas lanceolata* (Forssk.) Defflers. were collected from fully grown plant from Kanpur Dist. Uttar Pradesh, India. The plant as well as plant material was authenticated by Botany department, Rajasthan University, Jaipur Rajasthan. A voucher specimen (RUBL/16/20856) has been kept in herbarium in Department of Botany, University of Rajasthan, Jaipur, Rajasthan.

### Chemicals and Reagents

All the chemicals and reagents used were of extra pure and analytical Grade, procured from Sigma Chemical Pvt Ltd, USA. All solvents were obtained from Fischer Scientific Ltd, India.

### Phytochemical Screening

The phytochemical screening was done as per standard procedures to analyse secondary plant metabolite. Phytochemical testing usually analyses the content of plant secondary metabolites including glycosides, flavonoids, terpenoids, alkaloids, steroids and saponins<sup>[16-17]</sup>.

### Preparation of Extracts

The extraction of well dried coarsely powdered leaves of *Pentas lanceolata* was done by using *Soxhlet extraction* method. In this method of extraction, the pre-weighted plant material (500gm) was placed in *siphon tube* and the selected solvents (900 ml each) as Methanol and n-Hexane individually was taken in round bottom flask connected with siphon tube via condenser. The whole process takes up to 4-6 hrs for each solvent. After complete extraction

cool the extracts and were collected in concentrated form. The percentage yields of extracts for individual solvents were calculated in reference to material taken initially. The plant extracts were dissolved in distilled water for *in vivo* experiments [18].

### **Experimental Animals**

Male wistar rats having body weight **180–280 gm** were used for the experiments. The animals were housed under standard ecological conditions and were fed with standard pelleted diet and water *ad libitum*. All the experimental protocols were followed by as per suggestion of **CPCSEA** guidelines.

Before the study the ethical clearance was taken from Institutional Animal Ethics Committee (IACE). Procedures adopted in the animal study by using different models for toxicity profiling as well as Anti-arthritis activity was approved by Institutional Animal Ethical committee, NIMS University, Jaipur Rajasthan (NIMSUR/IAEC/CERT/2014/09/02) (Registration No. 302/ac/CPCSEA).

### **Acute Oral Toxicity Study**

Acute oral toxicity study for methanol and n-Hexane extract was conducted as per OECD guidelines 425. For the study healthy wistar rats of either sex having weight 190-300 gm were selected. The housing condition for the animals was maintained in polypropylene cages at the room temperature ( $25\pm 2^{\circ}\text{C}$ ), humidity ( $55\pm 5\%$ ) and 12 hrs of light and dark cycle [19]. For experimental protocol the animals were fasted before the study for whole day. On next day, the fasted animals were divided into six groups given the extracts at dose 100, 250, 500, 1000 and 2000 mg/kg body weight in diluted form with distilled water via oral route of drug administration. After 24 hrs the mortality counted and LD50 was determined.

### **Complete Freund's Adjuvant (CFA)-Induced Arthritis in Rats: -**

#### **Experimental Setup**

Total forty-two animals were divided into seven groups containing six animals each. The study period was directed from day 0 to day 28 into two different intervals as 0 – 14 days (developing phase) and 14–28 days (developed phase) [20]. Indomethacin, as standard drug and methanolic extract and n-hexane extract of *P. lanceolata* with 1% solution of sodium carboxy methyl cellulose (SCMC) was administered immediately as follows: -

**Group I: Normal control:** Received aqueous solution of 1% **SCMC** (Sodium Carboxy Methyl cellulose)

**Group II: Negative control:** (arthritis induced rats without any treatment)

**Group III: Positive control:** received 10 mg/kg per oral (p.o.) of Indomethacin

**Group IV:** Methanolic extract of *P. lanceolata* (**MEPL**) received 250 mg/kg p.o. for 28 days from the day of induction of arthritis (developing phase)

**Group V:** n-Hexane extract of *P. lanceolata* (**HEPL**) 250 mg/kg p.o. for 28 days from the day of induction of arthritis (developing phase)

**Group VI:** MEPL received 250 mg/kg p.o. for 14 days from the 14th day of induction of arthritis (developed phase)

**Group VII:** HEPL received 250 mg/kg p.o. for 14 days from the 14th day of induction of arthritis (developed phase)

### **Induction of Arthritis**

The rats were injected with 0.1 ml of the CFA (each ml CFA composed of 1 mg *Mycobacterium tuberculosis* heat kill and dried + 0.25 ml mineral oil + 0.15 ml mannide mono oleate) by sub plantar region in the left hind paw<sup>[21]</sup>. After the injection of CFA, the total paw volume of left hind paw of all the animals was measured using plethysmometer at 0, 5, 9, 14, 19, 23 and 28 days.

### **Total Arthritic Score**

The degree and score of arthritis was observed daily by means of a scale from 0 to 4 for each paw, targeting for a maximum score of 8 per rat. After induction of arthritis, the joint diameters of the right hind paw were measured using an electronic Vernier calliper. The grading criteria are mentioned below:

Standard paw = 0, Gentle inflammation and erythema of digits = 1, Normal inflammation and erythema of the digits = 2, Rigorous inflammation and erythema = 3, Net distortion and failure to use the limb = 4 on particular days. Thus, the highest possible score for both hind paws was 8<sup>[22]</sup>.

### **Total Paw Volume: -**

The total paw volume of left hind paw of all experimental drug treated animals were considered just prior to **Freund's complete adjuvant** injection on **day 0** and after that at various time durations till **day 28** using a plethysmometer. The changed paw volume observed was calculated as the distinction of the final and early paw volumes<sup>[23]</sup>.

### **Study of Haematological Parameters**

On 28<sup>th</sup> day the blood sample was collected by ocular puncture to investigate haematological parameters. The blood sample was stored in EDTA treated sample bottles. The standard method prescribed by *Chesbrough and McArthur* was adopted to count out the red blood cells and White blood cells individually<sup>[24]</sup>. To find out the level of blood haemoglobin the

standard method suggested by *Drabkin and Austin* was adopted<sup>[25]</sup>. To estimate ESR the standard method suggested by *Westergren and Wintrobe* was applied<sup>[26]</sup>.

### **Study of Biochemical Parameters**

For the estimation biochemical parameters like Anti-oxidants (SOD, Catalase and GSH), Total proteins, Serum bilirubin, liver function tests (SGOT and SGPT), Alkaline phosphate, Hydroxyproline and Hexosamine, the standard procedures were adopted<sup>[27-32]</sup>.

### **Radiological Study**

Radiographs were taken for the hind paw of all the experimental animals and inspected for soft tissue inflammation, bone destructions and contraction of spaces between the joints<sup>[33]</sup>.

### **Histopathological studies**

The interphalangeal joints were removed from the hind paw, washed with saline and fixed for 24 hrs. in formalin (10%). After decalcification, the sections obtained were stained with eosin haematoxylin stain and viewed under magnification of 100x.

### **Statistical Analysis**

The results were expressed as mean  $\pm$  SEM. The statistical comparison was made between arthritic control and the treated groups. They were analysed by one-way ANOVA followed by Dunnett's & Turkey's multiple comparison test. The level of significance was set at  $p < 0.05$ .

## **RESULTS**

### **Preliminary Phytochemical Screening**

The percentage yield of the Methanolic extracts and n-hexane extracts obtained were calculated as 31.19% and 26.07% w/w respectively. Preliminary phytochemical examinations revealed the presence of glycosides, alkaloids, amino acids/protein, steroids and terpenoids in methanolic extract, whereas n-hexane extract showed the presence of glycosides, tannins, flavonoids, alkaloids, sterol and terpenoids.

### **Acute Oral Toxicity Study**

Methanolic extract and n-Hexane extract did not show any toxic or harmful effects upto 2000 mg/kg oral dose which indicates non-toxicity even at higher doses. The LD<sub>50</sub> of MEPL % HEPL was found to be greater than 2000 mg/kg. As a result, 250 mg/kg was selected as the dose in order to evaluate comparative in vivo antiarthritic activity in Freund's adjuvant induced arthritic rat model.

### **Total Arthritic Score**

All the groups of animals administered with Freund's complete adjuvant raised symptoms of clinical inflammation in one or more hind paws, assumed a biphasic response (Table 1). The initial symptom of ailment was **erythema** of one or more ankle joints. There was a primary growth in the signs of inflammation from **day 1** of drug treatment to **day 7**, followed by a minute decrements symptom of inflammation from day 8 to 14 (Figure 1).


**Table 1. Effect of Methanolic and n-Hexane extracts on Arthritic Index–**

Experimental Groups	Arthritic Index (on Days)					
	5 <sup>th</sup> Day	9 <sup>th</sup> Day	14 <sup>th</sup> Day	19 <sup>th</sup> Day	23 <sup>rd</sup> Day	28 <sup>th</sup> Day
Group I	2.63±0.9	2.75±0.60	2.71±0.50	2.62±0.87	2.53±0.56	2.54±0.23
Group II	3.77±1.03	4.87±1.01	5.54±1.04	5.95±1.00	6.23±1.10	6.19±1.09
Group III	3.73±1.04 b*	4.77±1.03 b*	3.68±1.06 b*	3.02±0.78 b*	2.73±0.58 b*	2.28±0.38 b*
Group IV	3.67±1.06 b*c*	4.57±0.79 b*c*	3.54±0.90 b*c*	2.89±0.67 b*c*	2.56±0.67 b*c*	2.21±0.33 b*c*
Group V	3.96±1.02 b*c*	4.89±1.01 b*c*	3.71±0.89 b*c*	2.99±0.55 b*c*	2.45±0.43 b*c*	2.11±0.61 b*c*
Group VI	4.09±0.09 b*c*	3.67±0.88 b*c*	3.04±0.76 b*c*	2.48±0.51 b*c*	2.23±0.45 b*c*	2.15±0.54 b*c*
Group VII	4.26±1.00 b*c*	3.86±0.08 b*c*	3.23±0.65 b*c*	2.67±0.43 b*c*	2.26±0.52 b*c*	2.18±0.44 b*c*

Group I: Normal control, Group II: Negative control, Group III: Positive control, Group IV: MEPL (28 days drug treatment), Group V: HEPL (28 days drug treatment), Group VI: MEPL (14 days drug treatment), Group VII: HEPL (14 days drug treatment). Values are expressed as mean ± SEM, n=6 animals in each group. Comparisons were made between: **b**: Group II vs. groups III, IV, V, VI and VII. **c**: Group III vs. groups IV, V, VI and VII.

\*Represents the statistical significance at **p < .05**.

**Figure 1. Effect of Methanolic and n-Hexane extracts on Arthritic Index–**



Values are expressed as **Mean  $\pm$  SEM of n=6 animals**. Statistically significant when **P < 0.05**.

### Total Paw Volume

There was a considerable improvement in paw volume in all Complete Freund's adjuvant (CFA) groups when compared to vehicle control but this development in paw volume was a biphasic response, i.e. there was a negligible decrease in paw volume from **day 09 to 23** but. The paw volume was furthestmost on **day 5<sup>th</sup>** in all Complete Freund's adjuvant administered rats. On treatment with MEPL & HEPL (250 mg/kg) significantly (**P < 0.01**) diminish the paw volume, analysed till **28<sup>th</sup> day**. (Table 2) (Figure2).


**Table 2. Effect of Methanolic and n-Hexane extracts on Paw Volume –**

Groups/ Days	1 <sup>st</sup>	5 <sup>th</sup>	9 <sup>th</sup>	14 <sup>th</sup>	19 <sup>th</sup>	23 <sup>rd</sup>	28 <sup>th</sup>
<b>Group I</b>	1.44 $\pm$ 0.076	1.72 $\pm$ 0.11	1.43 $\pm$ 0.06	1.46 $\pm$ 0.08	1.45 $\pm$ 0.10	1.56 $\pm$ 0.09	1.27 $\pm$ 0.06
<b>Group II</b>	1.26 $\pm$ 0.04*	3.49 $\pm$ 0.13*	2.95 $\pm$ 0.09*	2.68 $\pm$ 0.15*	2.44 $\pm$ 0.25*	2.34 $\pm$ 0.13*	2.17 $\pm$ 0.06*
<b>Group III</b>	1.12 $\pm$ 0.09 b*	2.29 $\pm$ 0.80 b*	2.40 $\pm$ 0.82b*	1.82 $\pm$ 0.16 b*	1.70 $\pm$ 0.13 b*	1.63 $\pm$ 0.14 b*	1.21 $\pm$ 0.11b*
<b>Group IV</b>	1.17 $\pm$ 0.11 b*c*	2.45 $\pm$ 0.09b*c*	2.24 $\pm$ 0.08b*c*	1.92 $\pm$ 0.13b*c*	1.66 $\pm$ 0.14b*c*	1.63 $\pm$ 0.11b*c*	1.36 $\pm$ 0.11b*c*



<b>Group V</b>	1.24± 0.09b*c*	2.36± 0.11b*c*	2.19± 0.09b*c*	1.99± 0.08b*c*	1.71± 0.12b*c*	1.67± 0.09b*c*	1.37± 0.11b*c*
<b>Group VI</b>	1.19± 0.08b*c*	2.32± 0.10b*c*	2.02± 0.09b*c*	1.88± 0.11b*c*	1.63± 0.10b*c*	1.52± 0.07b*c*	1.31± 0.11b*c*
<b>Group VII</b>	1.31± 0.11b*c*	2.49±0.12 b*c*	2.13±0.11 b*c*	1.98±0.09 b*c*	1.77±0.10 b*c*	1.64±0.09 b*c*	1.29±0.09 b*c*

**Figure2. Effect of Methanolic and n-Hexane extracts on Paw Volume–**



Group I: Normal control, Group II: Negative control, Group III: Positive control, Group IV: MEPL (28 days drug treatment), Group V: HEPL (28 days drug treatment), Group VI: MEPL (14 days drug treatment), Group VII: HEPL (14 days drug treatment). Values are expressed as Mean  $\pm$  SEM, n =6 animals in each group. Comparisons were made between: **b**: Group II vs. groups III, IV, V, VI and VII; **c**: Group III vs. groups IV, V, VI and VII. \*Represents the statistical significance at **p<.01**.

### Haematological Parameters


A considerable decline in the levels of **Hb** and **RBCs** was resulted out in control group when compared to Normal group. On treatments of **MEPL & HEPL** (250mg/kg) to Test Groups (**Group IV, V, VI and VII**) improved the levels of RBC and Hb to comparison with normal

levels. The improvement in **WBC** count and **ESR** were significantly increased in the Test Groups (Group IV, V, VI and VII)(Table 3) (Figure 3).

**Table3. Effect of MEPL & HEPL on Haematological Parameters: -**

Treatment Groups	RBC (Millions/mm <sup>3</sup> )	WBC (Thousands/mm <sup>3</sup> )	Hb (gm/dL)	ESR (mm/hr)
Group I	7.23 ± 0.53	9.82 ± 0.17	12.21 ± 0.27	9.19 ± 0.21
Group II	5.46 ± 0.24*	21.12 ± 1.09*	9.99 ± 0.23*	21.02 ± 1.76*
Group III	7.97 ± 0.49 b*	11.93 ± 0.87 b*	12.07 ± 0.33 b*	10.32 ± 1.05 b*
Group IV	7.26 ± 0.32 b*c*	15.45 ± 0.32 b*c*	12.02 ± 0.09 b*c*	9.73 ± 0.56 b*c*
Group V	7.53 ± 0.29 b*c*	16.25 ± 0.42 b*c*	11.89 ± 0.53 b*c*	9.67 ± 0.54 b*c*
Group VI	7.78 ± 0.56 b*c*	16.78 ± 0.59 b*c*	11.93 ± 0.41 b*c*	10.03 ± 0.78 b*c*
Group VII	7.32 ± 0.43 b*c*	15.98 ± 0.37 b*c*	11.69 ± 0.26 b*c*	9.97 ± 1.12 b*c*

**Figure 3. Effect of MEPL & HEPL on Haematological Parameters: -**



**RBC:** Red blood cell, **WBC:** White blood cell, **Hb:** Haemoglobin, **ESR:** Erythrocyte sedimentation rate.

Group I: Normal control, Group II: Negative control, Group III: Positive control, Group IV: MEPL (28 days drug treatment), Group V: HEPL (28 days drug treatment), Group VI: MEPL (14 days drug treatment), Group VII: HEPL (14 days drug treatment). Values are expressed as mean ± SEM, n = 6 animals in each group. Comparisons were made between: **b:** Group II vs.

groups III, IV, V, VI and VII. **c**: Group III vs. groups IV, V, VI and VII. \*Represents the statistical significance at  $p < .05$ .

### Biochemical Parameters


#### A. Effect on Anti-oxidant Enzymes

CFAs treated group resulted that the levels of **nitric oxide (NO)** and **Malondialdehyde** were **improved** considerably, while all the endogenous antioxidants were **reduced** significantly in arthritic Groups. The effect of **Test Compounds** significantly **reversed** the above changes. Treatment with MEPL & HEPL **enhanced** the presentation of **GSH** that of the CFAs group, while **Indomethacin (IMN)** was neutral for GSH performances. There was no regulative effect of MEPL & HEPL on the activity of SOD, whereas significantly increase the action of SOD of the test groups, and higher than the control group. (**Table 4**) (**Figure 4**).

**Table 4. Effect of MEPL & HEPL on Anti-oxidant Enzymes:**

Groups	GSH (U/mg Protein)	Catalase (U/mg Protein)	SOD (U/min/mg Protein)	Total Protein (mg/ml)
Group I	7.845 ± 0.39	1.521 ± 0.09	1.765 ± 0.18	9.71 ± 0.55
Group II	4.761 ± 0.59*	0.203 ± 0.05*	0.518 ± 0.16*	5.31 ± 0.32*
Group III	7.534 ± 0.34 b*	1.073 ± 0.14 b*	1.721 ± 0.18 b*	11.03 ± 0.61 b*
Group IV	8.012 ± 0.23 b*c*	0.865 ± 0.03 b*c*	1.563 ± 0.21 b*c*	9.41 ± 0.24 b*c*
Group V	7.983 ± 0.26 b*c*	0.824 ± 0.04 b*c*	1.612 ± 0.19 b*c*	9.12 ± 0.29 b*c*
Group VI	8.022 ± 0.21 b*c*	0.835 ± 0.03 b*c*	1.592 ± 0.18 b*c*	9.55 ± 0.31 b*c*
Group VII	8.098 ± 0.29 b*c*	0.876 ± 0.06 b*c*	1.623 ± 0.22 b*c*	9.03 ± 0.27 b*c*

**Figure 4. Effect of MEPL & HEPL on Anti-oxidant Enzymes:**




**GSH:**Glutathione, **SOD:**Superoxide dismutase. Group I: Normal control, Group II: Negative control, Group III: Positive control, Group IV: MEPL (28 days drug treatment), Group V: HEPL (28 days drug treatment), Group VI: MEPL (14 days drug treatment), Group VII: HEPL (14 days drug treatment). Values are expressed as mean  $\pm$  SEM, n =6 animals in each group. Comparisons were made between: **b:** Group II vs. groups III, IV, V, VI and VII. **c:** Group III vs. groups IV, V, VI and VII. \*Represents the statistical significance at  $p < .05$ .

#### B. Effect on Serum Enzyme Levels:

As a result of oedema induced by **CFA**, the levels of **SGPT**, **SGOT** and **ALP** were enhanced in all arthritis groups as compared to control groups. After treatment with MEPL & HEPL, the levels of these enzymes were significantly reduced in Test compounds **250mg/kg** groups as compared to control group. **Indomethacin** (100mg/kg) treatment not permitted biochemical changes to a greater degree than the test doses. The **SGOT**, **SGPT**, **ALP** and **Bilirubin** levels of all the groups were determined and compared with each other.(Figure 5).

**Figure 5. Effect of MEPL & HEPL on Serum Enzyme Levels:**




**SGOT**:Serum glutamic-oxaloacetic transaminase, **SGPT**:Serum glutamic pyruvic transaminase, **ALP**: Alkaline phosphatase. Group I: Normal control, Group II: Negative control, Group III: Positive control, Group IV: MEPL (28 days drug treatment), Group V: HEPL (28 days drug treatment), Group VI: MEPL (14 days drug treatment), Group VII: HEPL (14 days drug treatment). Values are expressed as mean  $\pm$  SEM, n =6 animals in each group. Comparisons were made between: **b**: Group II vs. groups III, IV, V, VI and VII. **c**: Group III vs. groups IV, V, VI and VII. \*Represents the statistical significance at  $p < .05$ .


### C. Effect on Hydroxyproline and Hexosamine:

Administration of **Indomethacin** in rats resulted in a considerable elevation in the levels of **Hydroxyproline** and **hexosamine** along with enhance the paw thickness. On pre-treatment of **MEPL & HEPL** with dose of 250mg/kg the level was unchanged.(**Figure6**).

Figure 6. Effect of MEPL & HEPL on Hydroxyproline & Hexosamine:




Radiological Study



**Figure 7.** Radiographs of hind legs in adjuvant-induced arthritic rats. **Group I:**Normal control,**Group II:**Negative control, **Group III:** positive control,**Group IV:** MEPL (28 days treatment),**Group V:**HEPL(28 days treatment),**Group VI:**MEPL (14 days treatment),**Group VII:**HEPL(14 days treatment).

#### Histopathological studies



**Figure 8.** Histopathology of proximal interphalangeal joints on adjuvant-induced arthritic rats.**Group I:**Normal control,**Group II:**Negative control, **Group III:** positive control,**Group IV:** MEPL (28 days treatment),**Group V:**HEPL(28 days treatment),**Group VI:**MEPL (14 days treatment),**Group VII:**HEPL(14 days treatment).

#### DISCUSSION

The % yields of the methanolic and n-hexane extracts were calculated and were subjected to preliminary phytochemical analysis to identify the phytoconstituents present. Acute toxicity study was conducted as per OECD guideline 425. The MEPL and HEPL did not confirm any toxic effects or deadliness at the limit dose of 2000 mg/kg p.o. for each extract, which represented that the extracts are safe to use at higher doses.

Variations in the paw volume of the adjuvant-induced arthritic rats were determined using digital plethysmometer. From the results obtained, it was observed that both MEPL and HEPL were effective inequivalent to the standard drug Indomethacin on falling the increase in paw volume. Further, the effects of MEPL & HEPL were also substantial in developing phase relatively the developed phase of arthritis. The decline in the RBC & Haemoglobin count and

haemoglobin level in the arthritic control group confirms the anaemic condition in arthritic rats. Anaemia is the most common extra-articular index of rheumatoid arthritis, estimated to occur in 30% to 60% patients<sup>[34]</sup>. The two most common reasons for anaemia in arthritic patients are gastrointestinal blood loss from arthritic medication and bone marrow changes in patients with inflammatory arthritis which prevents the release of iron for incorporation into the RBC's. MEPL, HEPL and Indomethacin-treated groups showed significant reversion from anaemia. The WBC count was reported to be increased in arthritic control rats, because of the stimulation of the immune system against the invasive antigens and the substantial decrease in MEPL and HEPL treated groups showed its immunomodulation effect<sup>[35]</sup>. The ESR reported as declined in extract treated groups significantly compared to standard drug.

In reference to biochemical parameters, the CFA treated groups indicate the elevated levels of nitric oxide (NO) and Malondialdehyde in all arthritic groups, while the levels of all the endogenous antioxidants were reduced significantly in all arthritic groups. These changes in the levels were vice versa in MEPL & HEPL treated groups of animals. Furthermore, HEPL & MEPL treated groups represent that the performance of GSH was increased in the model group, whereas Indomethacin (IMN) as a standard drug was neutral for the GSH performances. MEPL & HEPL had no significant effect on the activity of SOD, whereas they considerably enhance the action of SOD of the test groups, and was greater than the control group.

The anti-arthritic effect of the MEPL & HEPL is also supported by the effect of these extracts on serum enzyme levels. The levels of SGPT, SGOT and ALP were improved in all arthritic groups in comparison to control groups of CFA treatment. MEPL & HEPL leads to these enzymes level and effective to maintain these levels of the enzymes. Both the extracts with the dose of 250mg/kg show valuable reduction in the levels of serum enzymes in comparison to control group. Indomethacin (100mg/kg) treatment showed almost neutral effect and barred biochemical variations to a larger level than the test doses. Indomethacin also resulted in a considerable enhancement in the levels of **Hydroxyproline** and **hexosamine** along with the paw thickness. These changes were withdrawn by the pre-treatment of MEPL & HEPL with dose of 250mg/kg. in developing and developed phase respectively.

Histopathological study expressed the differences in the normal ankle joint and adjuvant-induced arthritic rat joint. The study of the histopathological parameters of hind paw joints in arthritic control rats also represented the prominent abnormalities like destruction of the bone marrow and extensive infiltration of the cells in the articular surface. MEPL and HEPL



treatment have shown marked reduction in all the above-mentioned pathological situations, signifying its effective antiarthritic activity by protecting the bone from degeneration.

Radiographic study of the MEPL and HEPL was found to be effective in reducing the soft tissue swelling and reduction of joint spaces, especially in the developing phase of arthritis. The radiographic report confirms the effective antiarthritic activity of MEPL and HEPL.

## CONCLUSION

On assessing the *in vivo* antiarthritic activity of MEPL and HEPL, the effects of both extracts were found to be significant, especially in the developing phase of arthritis. The antiarthritic activity of the MEPL and HEPL was significant, may be due to the presence of phytoconstituents such as saponin and anthraquinone glycosides, 3-o- $\beta$ -fucoryl-quinioic acid, Quermiside and rubiadin-1-methyl-3-o- $\beta$ -primeveroside etc. Alkaloids like speciophylline and pentacyclic indole alkaloid inophyllins and triterpenoids may be also responsible for the activity. Further, it authenticates the traditional use of *Pentas lanceolata* leaves in the treatment of rheumatism. However, further studies are necessary to recognize the active phytoconstituent

responsible for the antiarthritic activity. The molecular mechanism involved in the antiarthritic activity of the plant extracts of *Pentas lanceolata*, especially MEPL, can be studied in future to develop it as an alternative treatment for rheumatoid arthritis.

## ACKNOWLEDGMENT

The authors would like to thank the Management of Pranveer Singh Institute of Technology, Kanpur Uttar Pradesh and NIMS University, Jaipur Rajasthan for providing the necessary facilities to carry out this research work.

## AUTHORS CONTRIBUTIONS

Dr. Pranay Wal gave a substantial contribution by executing the experimental work in the laboratories, drafted the manuscript and extensively revised to improve the quality of the manuscript. Conception, the design of the study and supervision of the work were done by Dr. Awani Kumar Rai.

## CONFLICT OF INTERESTS

We declare that there were no conflicts of interest.

## REFERENCES

1. Chunxia C, Peng Z, Huifang P, Hanli R, Zehua H, Jizhou W. Extracts of *Arisaema rhizomatum* C.E.C. Fischer attenuate inflammatory response on collagen-induced arthritis in BALB/c mice. *J Ethnopharmacol.* 2011. 133, 573-582.

2. Hooi Yeen Y, Sabrina Zi Yi T, Magdelyn Mei T W, Sook Khuan C, Suat Cheng P, Sin Yeang T. Pathogenic Role of Immune Cells in Rheumatoid Arthritis: Implications in Clinical Treatment and Biomarker Development Cells.2018. 7, 10, 161.
3. Heijde DM.Plain X-rays in rheumatoid arthritis: overview of scoring methods, their reliability and applicability. *Baillieres Clin Rheumatol.* 1996.10, 3, 435-453.
4. Arnett F, Edworthy S, Bloch D.American Rheumatism Association, Revised Criteria for the Classification of Rheumatoid Arthritis in *Arthritis and Rheumatism.* 1987. 31, 3.
5. Narendhirakannan RT, Subramanian S, Kandaswamy M.Anti-inflammatory and lysosomal stability actions of *Cleome gynandra L.* studied in adjuvant induced arthritic rats. *Food Chem Toxicol.* 2007 45, 1001–1012.
6. Kayanaugh A, Grevich SC. Rheumatoid arthritis. In: Kellerman RD, Bope ET editors.*Conn’s Current Therapy.* 70th ed. Elsevier; Atlanta, GA, USA.2018. 2. 899-903.
7. Yeom MJ, Lee HC, Kim GH, Lee HJ, Shim I, Oh SK, Kang SK, Hahm DH. Anti-arthritic effects of *Ephedra sinica* STAPF herb-acupuncture: inhibition of lipopolysaccharide-induced inflammation and adjuvant induced polyarthritis. *J Pharmacol Sci.* 2006. 100, 41-50.
8. Emmanuel JH, Montgomery RD.Gastric ulcer and the anti-arthritic drugs. *Postgrad Med J.*1971. 47, 227-232.
9. Singh G, Ramey DR, Morfeld D, Shi H, Hatoum HT, Fries JF.Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. *Arch Intern Med.* 1996. 156, 530-1536.
10. Gaffo A, Saag KG, Curtis JR.Treatment of rheumatoid arthritis. *Am J Health Syst Pharm.* 2006. 63, 2451-2465.
11. Mirutse G, Zemedede A, Zerihun W.Medicinal plants of the Meinit ethnic group of Ethiopia: An ethnobotanical study, *J. Ethnopharmacol.* 2009. 10, 1016, 09-1016.
12. Tilahun T, Mirutse G, Zemedede A, Zerihun W. Medicinal plant knowledge of the Bench ethnic group of Ethiopia: an ethnobotanical investigation, *J Ethnobiol Ethnomed.* 2009. 5, 34.
13. Taddeo A, Claude K.Qualitative (phytochemical) analysis and antifungal activity of *Pentas decora*, a plant used traditionally to treat skin fungal infections in Western Uganda, *Research in Pharmaceutical Biotechnology.* 2011. 3, 7, 75-84.

14. Endale M, Alao JP, Akala HM, Rono NK. 2012. Antiplasmodial quinones from *Pentas longiflora* and *Pentas lanceolata*. *Planta Med.* 78, 1, 31-5.
15. Suman D, Vishwanadham Y, Kumaraswamy T, Shirisha P, Hemalatha K. Phytochemical Evaluation and Analgesic Activity of *Pentas lanceolata* Leaves. *Nat Prod Chem Res.* 2014.2, 135.
16. Khandelwal KR, Pawar AP, Kokhale SB. *Practical Pharmacognosy*, Pune. Nirali Pakashan. 1995. 144-146.
17. Kokate CK. *Practical Pharmacognosy*, 4<sup>th</sup> ed. New Delhi. Vallabh Prakashan. 2005.
18. Wallis TE. *Practical Pharmacognosy*, J. & A. Churchill Ltd., London, England, 1967. 652.
19. Miller LC, Tainter ML. Estimation of LD50 and its error by means of log-probit graph paper. *Proc Soc Exp Bio Med.* 1944. 57, 261.
20. Sanmuga PE, Senthamil SP, Venkataraman S. Evaluation of antiarthritic activity of *Strychnos potatorum* Linn seeds in Freund's adjuvant induced arthritic rat model. *BMC Complement Altern Med.* 2010. 10, 2-9.
21. Newbould BB. Chemotherapy of arthritis induced in rats by mycobacterial adjuvant. *Br J Pharmacol Chemother.* 1963. 21, 127-136.
22. Pfeil A, Oelzner P, Bornholdt K, Hansch A, Lehmann G. Joint damage in rheumatoid arthritis: assessment of a new scoring method. *Arthritis Res. Ther.* 2013. 15, 27.
23. Fereidoni M, Ahmadiani A, Semnanian S, Javan M. An accurate and simple method for measurement of paw edema. *J Pharmacol Toxicol Methods.* 2000. 43, 11-14.
24. Chesbrough M, McArthur J. *Laboratory Manual of Rural Tropical Hospitals*. The English Language Book Society and Churchill Livingstone, London. 1972.
25. Austin JH, Drabkin DL. Estimation of Haemoglobin. *Journal of Biological Chemistry.* 1935. 11, 267-9.
26. David G, Sykes AJ. Westergren and Wintrobe methods of estimating ESR compared. *Br Med J.* 1951. 2, 4746, 1496-7.
27. Ismail NA, Okasha SH, Dhawan A, Rahman MOA, Hamid NA, Shaker O. Glutathione peroxidase, superoxide dismutase and catalase activities in children with chronic hepatitis. *Advances in Bioscience and Biotechnology.* 2012. 3, 972-977.
28. Weydert CJ, Cullen JJ. Measurement of superoxide dismutase, catalase, and glutathione peroxidase in cultured cells and tissue, *nat. protocol.* 2010. 5, 1, 51-66.
29. Van den Bergh AAH, Muller P. *A handbook of Haematology*, London, Hamish, Hamilton. 1918. 77, 90.

30. Al-Wakeel J, Malik GH, al-Mohaya S, Mitwalli A, Baroudi F, Gamal H. Liver disease in dialysis patients with antibodies to hepatitis C virus. *Nephrol Dial Transplant*.1996.11, 2265-8.
31. Beddhu S, Ma X, Baird B, Cheung AK, Greene T. Serum alkaline phosphatase and mortality in African Americans with chronic kidney disease. *Clin J Am Soc Nephrol*.2009. 4, 1805-10.
32. Neuman RE, Logan M. The determination of hydroxyproline. *J. Biol chem*.1950.184, 299-306.
33. Harris ED. Rheumatoid arthritis. Pathophysiology and implications for therapy. *N Eng. J Med*.1990. 322, 1277–1289.
34. Mowat AG. Hematologic abnormalities in rheumatoid arthritis. *Semin.Arthritis Rheum*.1971.1, 195–219.
35. Rajaram C, Ravindra Reddy K, B Chandra Sekhar K. Evaluation of antiarthritic activity of *Caesalpinia pulcherimma* in Freund's complete adjuvant induced arthritic rat model. *J Young Pharmacists*.2015. 7, 128–132.